• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Revelyst Announces Chief Supply Chain Officer

    4/23/24 7:00:00 AM ET
    $BDX
    $EMBC
    $VSTO
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BDX alert in real time by email

    Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer.

    Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply chain, sourcing and logistics leader is key to helping Revelyst and its brands begin this new chapter.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423438660/en/

    Joe Beck, Chief Supply Chain Officer for Revelyst (Photo: Business Wire)

    Joe Beck, Chief Supply Chain Officer for Revelyst (Photo: Business Wire)

    Beck most recently served as Vice President of Global Supply Chain for embecta (NASDAQ:EMBC), a medical technology company where he oversaw global supply chain and distribution operations, including the overhaul of their global network design, planning, logistics, and trade technology and change management leadership. Beck was part of embecta's leadership team executing the separation from Becton Dickinson and Co. (NYSE:BDX). During the transition, he helped establish the company's supply chain infrastructure while ensuring continuity of supply and mitigating customer disruptions. His ability to design and deploy global supply chain operations for a standalone business — including hiring talent, building effective teams and developing processes, analytics and technology — made him an ideal candidate to be Revelyst's first Chief Supply Chain Officer.

    "Bringing a change agent like Joe to Revelyst's leadership team is critical for our goal of becoming the industry's No. 1 house of brands," said Eric Nyman, CEO of Revelyst. "He has a unique talent for transforming a company's supply chain by consolidating facilities and building new capabilities, which have a direct impact on the bottom line. Joe will help revolutionize Revelyst at the enterprise, platform and brand level, and we welcome his innovative thinking as we continue to build our culture of empowerment and excellence."

    Before embecta, Beck worked for Medtronic and UPS, two global Fortune 500 companies where he streamlined and optimized supply chain operations, which he will replicate and enhance in this new role. Beck is the latest executive to join Revelyst's growing management team, including Nyman, CFO Andy Keegan, General Counsel Jung Choi and CHRO Joyce Butler. The addition of Beck will provide Revelyst with the supply chain and sourcing savvy needed in an increasingly competitive and complex global economy.

    "This is the opportunity of a lifetime because it combines my outdoor passions with my love of helping companies become more efficient and effective moving products and information across the global supply chain," said Beck. "I look forward to building a world-class team whose sole focus is optimizing the way Revelyst does business, building scale across our portfolio and developing innovative strategies that give our company and our brands a significant competitive advantage to accelerate growth."

    About Revelyst

    Revelyst, a segment of Vista Outdoor Inc. (NYSE:VSTO), is a collective of world-class maker brands that design and manufacture performance gear and precision technologies. Our category-defining brands leverage meticulous craftsmanship and cross-collaboration to pursue new innovations that redefine what is humanly possible in the outdoors. Portfolio brands include Foresight Sports, Bushnell Golf, Fox, Bell, Giro, CamelBak, Bushnell, Simms Fishing and more. For more information, visit our website at www.revelyst.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240423438660/en/

    Get the next $BDX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDX
    $EMBC
    $VSTO

    CompanyDatePrice TargetRatingAnalyst
    Becton Dickinson and Company
    $BDX
    9/25/2025$211.00Sector Perform
    RBC Capital Mkts
    Becton Dickinson and Company
    $BDX
    5/22/2025$185.00Buy → Neutral
    Citigroup
    Becton Dickinson and Company
    $BDX
    5/2/2025$185.00Overweight → Neutral
    Piper Sandler
    Becton Dickinson and Company
    $BDX
    5/2/2025$192.00Buy → Neutral
    Goldman
    Becton Dickinson and Company
    $BDX
    5/2/2025Outperform → Mkt Perform
    Raymond James
    Becton Dickinson and Company
    $BDX
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    Becton Dickinson and Company
    $BDX
    5/1/2025$190.00Buy → Neutral
    BofA Securities
    Becton Dickinson and Company
    $BDX
    5/1/2025Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $BDX
    $EMBC
    $VSTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Duncan Regional Hospital Becomes First in U.S. to Implement BD Alaris™ EMR Infusion Interoperability with MEDITECH

    FRANKLIN LAKES, N.J., Nov. 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Duncan Regional Hospital ("DRH Health") has become the first hospital in the United States to implement BD Alaris™ EMR (Electronic Medical Record) Interoperability with the MEDITECH electronic health record (EHR), marking a significant advancement in patient safety, workflow efficiency and clinician support. This integration brings together BD's robust market-leading bi-directional infusion interoperability – now l

    11/13/25 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Expands PureWick™ Portfolio with First-of-its-Kind Portable Solution to Confidently Manage Urinary Incontinence On the Go

    FRANKLIN LAKES, N.J., Nov. 12, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, introduces the PureWick™ Portable Collection System, a discreet, first-of-its-kind, battery-powered personal urine management device designed for wheelchair users to help improve mobility around and outside the home. The PureWick™ Portable Collection System builds on the success of the PureWick™ Urine Collection System, the #1 external catheter used in hospitals. The non-invasive device uses gentle suction technology that draws voided 

    11/12/25 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    embecta to Report Fiscal Fourth Quarter and Full Year 2025 Financial Results

    PARSIPPANY, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal fourth quarter and full year 2025 financial results and provide an operational update, including preliminary fiscal year 2026 financial guidance, at 8:00 a.m. Eastern Time (ET) on Tuesday, November 25, 2025. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the c

    11/11/25 5:00:00 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Becton Dickinson with a new price target

    RBC Capital Mkts initiated coverage of Becton Dickinson with a rating of Sector Perform and set a new price target of $211.00

    9/25/25 8:27:46 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson downgraded by Citigroup with a new price target

    Citigroup downgraded Becton Dickinson from Buy to Neutral and set a new price target of $185.00

    5/22/25 8:18:13 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Becton Dickinson from Overweight to Neutral and set a new price target of $185.00

    5/2/25 8:06:47 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Scott Bertram L sold $38,318 worth of shares (217 units at $176.58), decreasing direct ownership by 0.60% to 35,816 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    11/7/25 5:36:46 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Byington Carrie L

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    11/4/25 8:41:02 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Jones Christopher Ian Montague

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    11/4/25 8:36:53 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    11/23/21 3:16:12 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

    For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

    7/23/21 4:06:11 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    SEC Filings

    View All

    Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    11/6/25 6:32:28 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    10/15/25 4:18:58 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Becton Dickinson and Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - BECTON DICKINSON & CO (0000010795) (Filer)

    9/17/25 8:46:05 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hayes Gregory bought $1,005,742 worth of shares (5,250 units at $191.57), increasing direct ownership by 660% to 6,046 units (SEC Form 4)

    4 - BECTON DICKINSON & CO (0000010795) (Issuer)

    8/11/25 4:15:55 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    Director Melcher David F bought $105,995 worth of shares (10,000 units at $10.60), increasing direct ownership by 13% to 86,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    5/23/25 4:35:56 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    2/25/25 4:26:16 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Vista Outdoor Inc.

    SC 13G - Vista Outdoor Inc. (0001616318) (Subject)

    12/2/24 4:30:15 PM ET
    $VSTO
    Ordnance And Accessories
    Industrials

    SEC Form SC 13G filed by Vista Outdoor Inc.

    SC 13G - Vista Outdoor Inc. (0001616318) (Subject)

    11/27/24 12:42:04 PM ET
    $VSTO
    Ordnance And Accessories
    Industrials

    Amendment: SEC Form SC 13G/A filed by Embecta Corp.

    SC 13G/A - Embecta Corp. (0001872789) (Subject)

    11/8/24 10:57:43 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Leadership Updates

    Live Leadership Updates

    View All

    BD Expands Peripheral Artery Disease Awareness Efforts with 'Love Your Limbs' Community Screening Initiative

    FRANKLIN LAKES, N.J., Sept. 2, 2025 /PRNewswire/ -- In recognition of Peripheral Artery Disease (PAD) Awareness Month, BD (Becton, Dickinson and Company) (NYSE:BDX) is shining a spotlight on a serious yet often overlooked circulatory disorder that restricts blood flow to the limbs and is a leading cause of preventable amputations. https://loveyourlimbs.com to learn more or get involved." alt="September is Peripheral Artery Disease Awareness Month. Visit https://loveyourlimbs.com to learn more or get involved."> PAD affects more than 21 million Americans1 and more than 200 milli

    9/2/25 6:50:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment

    FRANKLIN LAKES, N.J., July 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that, effective July 2, Bilal Muhsin has been named executive vice president and will become the president of BD's future Connected Care segment, as part of the company's previously announced plans to update its structure as it advances its New BD strategy. Mushin will serve as a member of the BD Executive Leadership Team reporting to Tom Polen, chairman, CEO and president of BD and will lead the strategy development to support an effective transition into this new structure over the next several months.

    7/7/25 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Names Gregory J. Hayes to Board of Directors

    FRANKLIN LAKES, N.J., March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Gregory J. Hayes to its board of directors, effective March 26, 2025. Hayes, 64, is currently the executive chairman of the board of directors of RTX Corporation, the world's largest aerospace and defense company. He brings more than 30 years of extensive executive experience, having held chief executive officer and senior leadership roles across finance, corporate strategy and business development f

    3/27/25 4:15:00 PM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    $BDX
    $EMBC
    $VSTO
    Financials

    Live finance-specific insights

    View All

    embecta to Report Fiscal Fourth Quarter and Full Year 2025 Financial Results

    PARSIPPANY, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal fourth quarter and full year 2025 financial results and provide an operational update, including preliminary fiscal year 2026 financial guidance, at 8:00 a.m. Eastern Time (ET) on Tuesday, November 25, 2025. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the c

    11/11/25 5:00:00 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    BD Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

    Q4 revenue of $5.9 billion increased 8.3% as reported, 7.0% FXN and 3.9% organicQ4 GAAP and adjusted diluted EPS grew to $1.72 and $3.96, respectivelyFY25 revenue of $21.8 billion increased 8.2% as reported, 7.7% adjusted FXN and 2.9% organicFY25 GAAP EPS of $5.82 decreased 0.7%; adjusted diluted EPS of $14.40 grew 9.6%FY25 GAAP and adjusted gross margin up 20 basis points and 140 basis points, respectively, driven by BD ExcellenceFY25 GAAP operating margin down 10 basis points to 11.8%; adjusted operating margin up 80 basis points to 25.0%Returned $2.2 billion to shareholders in FY25 through dividends and share repurchasesCompany issues FY26 guidanceFRANKLIN LAKES, N.J., Nov. 6, 2025 /PRNew

    11/6/25 6:30:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care

    BD Board Increases Dividend for 54th Consecutive Year

    FRANKLIN LAKES, N.J., Nov. 6, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of $1.05 per common share, an increase of 1.0% from the previous quarter. The dividend will be payable on December 31, 2025 to holders of record on December 8, 2025. The indicated annual dividend rate for fiscal year 2026 is $4.20 per share. "This is the 54th consecutive fiscal year in which we have raised our dividend, maintaining BD's membership in the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends for at least 25 consecutive years," said Tom Polen, chairman, CEO and president of BD. "This inc

    11/6/25 6:25:00 AM ET
    $BDX
    Medical/Dental Instruments
    Health Care